SOURCE: Industrial Info Resources

May 02, 2008 05:30 ET

Novavax Goes Through the Change as It Sheds Estrogen Drug to Focus on Vaccine Production, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - May 2, 2008) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--What a difference a day makes, or in the case of Novavax Incorporated (NASDAQ: NVAX) (Rockville, Maryland), just a few short years. Not long ago, the pharma company's sole product was estrogen-replacement therapy Estrasorb, and it was struggling as it was buried under a $35 million debt with only $5 million in cash and burning $2 million per month. Today, the company is flush with capital, some invested by its new partner GE Healthcare, a division of General Electric (NYSE: GE) (Fairfield, Connecticut), as it completes a shift in therapeutic focus to vaccine development and production.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=132279, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.

Contact Information

  • Contact:
    Joe Govreau
    713-783-5147